Methods of treating inflammation associated airway diseases and viral infections

1. A method of treating a viral influenza lung pathogen infection by controlling inflammation in a subject without substantially affecting viral burden in the subject, said method comprising the steps of:

i)administering an anti-S100A9 antibody to the subject in need of thereof; and

ii) assessing the viral burden in the subject.

2. The method of claim 1 , wherein the control of inflammation is a reduction in TNF-α, a reduction in IL-6, or both.

3. The method of claim 1 , wherein the control of inflammation is a reduction in TNF-α.

4. The method of claim 1 , wherein the control of inflammation is a reduction in IL-6.

5. The method of claim 1 , wherein the viral influenza lung pathogen is influenza A.

6. The method of claim 1 , wherein the method further comprises administering a second therapeutic agent in conjunction with the anti-S100A9 antibody, wherein the second therapeutic agent is an antiviral drug.

7. The method of claim 6 , wherein the second therapeutic agent is selected from the group consisting of amantadine, oseltamivir, zanamivir, ribavirin, and palivizumab.

8. The method of claim 1 , wherein the anti-S100A9 antibody is administered to the subject via a route selected the group consisting of inhalation to the respiratory system, instillation in the respiratory system, intraperitoneal injection, and intravenous injection.

9. The method of claim 1 , wherein the anti-S100A9 antibody is a humanized anti-S100A9 antibody.

10. The method of claim 1 , wherein the anti-S100A9 antibody is S100A9-binding antibody fragment or an antibody conjugate.

11. The method of claim 1 , wherein the anti-S100A9 antibody is S100A9-binding antibody fragment.

12. The method of claim 1 , wherein the reduction of inflammation in the lung of the subject without affecting viral burden of the lung pathogen infection of the subject is present within 3 days of administration of the anti-S100A9 antibody to the subject.